日本語 
Alloy Therapeutics Co. Ltd. (Alloy Japan) signed a Memorandum of Understanding (MOU) with the Kansai Startup Academia Coalition (KSAC). Kyoto University leads this coalition. Its goal is to help life science startups from Japanese universities grow globally. This partnership seeks to speed up research and development. It connects academic innovation with the global biopharmaceutical community.
KSAC is a coalition of over 90 academic institutions in western Japan, established under Kyoto University’s leadership and backed by Japan’s Ministry of Education, Culture, Sports, Science and Technology (MEXT). The coalition boosts early-stage research and entrepreneurship. It does this with GAP funding, digital workshops, educational programs, and technology showcases. These efforts connect academia and industry in the life sciences sector, both locally and globally.
Alloy Therapeutics Inc., headquartered in Boston, is a biotechnology ecosystem company committed to democratizing access to foundational biologics discovery platforms. Through its suite of technologies, discovery services, and venture studio 82VS, Alloy supports scientists and entrepreneurs worldwide in accelerating drug discovery. With the recent launch of its Japanese subsidiary, Alloy Japan, the company has expanded its focus to include iPS cell therapy development and regional ecosystem support across Japan and Asia.
Also Read: DRC Medicine Ltd to Merge with Ribbon Acquisition Corp.
Under the MOU, Alloy Japan and KSAC will work together to connect promising research from Japanese universities to global biopharma markets, while also channeling international expertise and opportunities back to Japan. The partnership seeks to enhance the nation’s academic and entrepreneurial infrastructure, fostering life science startups with global competitiveness.
“Alloy’s capabilities and global network bring a highly complementary strength to our mission of empowering academic startups to compete internationally,” said Koji Murota, Director-General of the Office of Institutional Advancement and Communications at Kyoto University, representing KSAC. “By collaborating with ecosystem builders like Alloy Japan, we can offer our researchers and entrepreneurs enhanced access to scientific resources, Biopharma insights, and global growth opportunities.”
As an initial step, Alloy Japan will contribute to KSAC’s GAP Fund program, which finances select academic projects within the coalition. Over the three-year term of the MOU, the partnership is expected to expand across additional KSAC initiatives to support a globally connected, innovation-led biotech community in Japan.
“Our collaboration with Kansai Startup Academia Coalition builds on Alloy Japan’s commitment to deep, sovereign partnerships that nurture innovation at the academic and early translational stages,” said Victor Stone (Yoshihide Ishii), CEO of Alloy Therapeutics Japan. “By working alongside KSAC and its university network, we aim to bridge Japanese academic excellence with the global Biopharma ecosystem and accelerate the global trajectory of Japan’s life science startups.”
English